Johnson & Johnson (NYSE:JNJ) Shares Acquired by Elo Mutual Pension Insurance Co


Elo Mutual Pension Insurance Co raised its stake in Johnson & JohnsonNYSE: JNJGet Votes) and 2.9% in the first quarter, according to the latest 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,647 shares of the company’s stock after acquiring an additional 5,742 shares during the period. Johnson & Johnson makes up about 1.0% of Elo Mutual Pension Insurance Co’s portfolio, making the stock its 14th largest position. Elo Mutual Pension Insurance Co’s holdings in Johnson & Johnson were worth $36,092,000 at the end of the most recent period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sloy Dahl & Holst LLC increased its holdings in Johnson & Johnson by 7.5% in the first quarter. Sloy Dahl & Holst LLC now owns 6,245 shares of the company’s stock worth $1,107,000 after buying an additional 436 shares during the period. WMS Partners LLC grew its holdings in shares of Johnson & Johnson by 3.5% in the first quarter. WMS Partners LLC now owns 75,996 shares of the company’s stock valued at $13,469,000 after acquiring an additional 2,586 shares in the last quarter. State Treasurer State of North Carolina increased its stake in shares of Johnson & Johnson by 1.2% in the first quarter. State Treasurer State of North Carolina now owns 1,171,014 shares of the company’s stock valued at $207,539,000 after acquiring an additional 14,123 shares during the period. Advisors Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 6.1% in the first quarter. Advisors Capital Management LLC now owns 284,971 shares of the company’s stock valued at $50,505,000 after purchasing an additional 16,467 shares during the last quarter. Finally, SILVER OAK SECURITIES Inc acquired a new position in Johnson & Johnson during the first quarter valued at $1,200,000. Institutional investors and hedge funds own 68.78% of the company’s stock.

Johnson & Johnson’s Sales Rise 1.5%

Sections a Johnson & Johnson company opinion opened at $169.31 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market capitalization of $445.15 billion, a PE ratio of 24.64, a P/E/G ratio of 3.17 and a beta of 0.59. The company’s 50-day moving average is $173.43 and its 200-day average is $174.56.

Johnson and Johnson (NYSE: JNJGet Votes) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a profit margin of 36.14% and a margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. In the same quarter last year, the business earned $2.48 per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Company Opinion

The company also announced a third quarter dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a $1.13 dividend. The company paid $4.52 per share during the last period and the annual yield was 2.67 %. The deadline to share is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Insider Transactions at Johnson & Johnson

In related news, the EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares traded at an average price of $173.00, for a total sale of $6,920,000.00. Following the completion of the transaction, the vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which can be accessed via This hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The coins were sold at a price of $173.00, for a price of $6,920,000.00. Following the completion of the sale, the vice president now owns 71,311 shares in the company, valued at $12,336,803. The project was revealed in a document issued by the Securities & Exchange Commission, which is available through SEC website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The coins were sold at a price of $180.00, for a price of $1,523,160.00. Following the sale, the chief financial officer now owns 15,473 shares in the company, valued at approximately $2,785,140. Disclosures for these products can be found Here. Insiders own 0.35% of the company’s stock.

Researchers Set New Price Targets

A number of research firms have weighed in on JNJ. Morgan Stanley lifted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. UBS Group reduced their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They put an “over” rating on the property. SVB Leerink dropped their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Finally, Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a target price of $189.89.

About Johnson & Johnson

(Get Votes)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells a variety of medical products worldwide. The company’s Consumer Health division offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the brand name LISTERINE; skin health / beauty products under AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Go to HoldingsChannel.com to access the latest 13F filings and Johnson & Johnson insider trading (NYSE: JNJGet Votes).



Receive Johnson & Johnson Daily News & Reviews – Enter your email address below to receive a concise daily summary of the latest news and ratings for Johnson & Johnson and related companies with MarketBeat.com ‘s FREE daily email newsletter.